BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9484827)

  • 1. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
    Volm M; Rittgen W; Drings P
    Br J Cancer; 1998 Feb; 77(4):663-9. PubMed ID: 9484827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas.
    Volm M; Drings P; Wodrich W
    J Cancer Res Clin Oncol; 1993; 119(9):507-10. PubMed ID: 8100821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
    Volm M; Efferth T; Mattern J
    Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.
    Volm M; Koomägi R; Mattern J
    Int J Cancer; 1997 Feb; 74(1):64-8. PubMed ID: 9036871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
    Volm M; Mattern J
    Anticancer Res; 1993; 13(6A):2021-5. PubMed ID: 8297109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas.
    Volm M
    Anticancer Res; 1993; 13(2):375-8. PubMed ID: 8100127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix.
    Lee IJ; Park KR; Lee KK; Song JS; Lee KG; Lee JY; Cha DS; Choi HI; Kim DH; Deung YK
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):768-79. PubMed ID: 12377329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.
    Shijubo N; Uede T; Kon S; Maeda M; Segawa T; Imada A; Hirasawa M; Abe S
    Am J Respir Crit Care Med; 1999 Oct; 160(4):1269-73. PubMed ID: 10508818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of oncoproteins in non-small cell lung carcinomas of smokers.
    Wodrich W; Volm M
    Carcinogenesis; 1993 Jun; 14(6):1121-4. PubMed ID: 8389672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
    O'Byrne KJ; Koukourakis MI; Giatromanolaki A; Cox G; Turley H; Steward WP; Gatter K; Harris AL
    Br J Cancer; 2000 Apr; 82(8):1427-32. PubMed ID: 10780522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas.
    Fontanini G; Boldrini L; Chinè S; Pisaturo F; Basolo F; Calcinai A; Lucchi M; Mussi A; Angeletti CA; Bevilacqua G
    Br J Cancer; 1999 Jan; 79(2):363-9. PubMed ID: 9888482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of glutathione S-transferase pi and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas.
    Yokoyama Y; Sagara M; Sato S; Saito Y
    Gynecol Oncol; 1998 Mar; 68(3):280-7. PubMed ID: 9570981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.
    Volm M; van Kaick G; Mattern J
    Clin Exp Metastasis; 1994 Jul; 12(4):329-34. PubMed ID: 7913670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma.
    Artese L; Rubini C; Ferrero G; Fioroni M; Santinelli A; Piattelli A
    Anticancer Res; 2001; 21(1B):689-95. PubMed ID: 11299827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
    Volm M; Koomägi R
    Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
    Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.
    Mineta H; Miura K; Ogino T; Takebayashi S; Misawa K; Ueda Y; Suzuki I; Dictor M; Borg A; Wennerberg J
    Br J Cancer; 2000 Sep; 83(6):775-81. PubMed ID: 10952783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas.
    Volm M; Mattern J; Koomägi R
    Anticancer Res; 1999; 19(3A):1669-71. PubMed ID: 10470099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quantitative study of vascular endothelial growth factor expression in primary lung cancer].
    Shi E; Jiang H; Xu S
    Zhonghua Yi Xue Za Zhi; 1999 Aug; 79(8):596-8. PubMed ID: 11715407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
    Mattern J; Koomägi R; Volm M
    Br J Cancer; 1996 Apr; 73(7):931-4. PubMed ID: 8611409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.